Company Overview

AirSculpt Technologies, Inc. is a U.S.-based cosmetic surgery and body contouring company that operates through a network of proprietary treatment centers branded as AirSculpt®. The company specializes in minimally invasive body sculpting procedures using its patented and trademarked fat removal and fat transfer technologies. AIRS operates within the elective medical aesthetics and cosmetic surgery industry, serving consumers seeking body contouring, fat reduction, skin tightening, and related aesthetic enhancement procedures.

The company’s primary revenue drivers are patient procedure fees generated through its owned and operated centers, with additional revenue derived from complementary aesthetic services and financing arrangements. AIRS markets its procedures as alternatives to traditional liposuction, emphasizing reduced downtime, local anesthesia, and minimally invasive techniques. The company traces its origins to physician-led cosmetic surgery operations founded by Dr. Aaron Rollins, who developed the AirSculpt methodology and expanded the business into a branded national platform. Following years of private expansion, the company became publicly traded on Nasdaq under the ticker AIRS in 2021.

Business Operations

AIRS primarily generates revenue through the operation of its AirSculpt Centers, which provide cosmetic procedures directly to patients. The company’s business model is vertically integrated, encompassing patient acquisition, physician staffing, clinical operations, marketing, and proprietary procedural protocols. Its portfolio of services includes fat removal, Brazilian Butt Lift procedures, body contouring, skin tightening, and fat transfer procedures targeting multiple demographic groups. Revenue is highly tied to procedure volume, pricing, and center utilization rates.

The company operates predominantly in the United States, while also maintaining select international operations. AIRS controls proprietary procedural techniques, trademarks, and patient management systems associated with the AirSculpt brand. The company has historically emphasized digital marketing and centralized lead generation as core operational capabilities. Public filings identify subsidiaries tied to clinical operations and administrative support functions, while the company’s physician network and clinic infrastructure remain central assets supporting expansion efforts.

Strategic Position & Investments

AIRS has focused its strategy on expanding the number of owned treatment centers, increasing procedure offerings, and strengthening brand recognition within the premium cosmetic surgery market. Management has consistently emphasized geographic expansion into affluent metropolitan markets with high demand for elective aesthetic procedures. The company has also invested in marketing infrastructure, physician recruitment, and operational standardization intended to support scalable growth across new and existing locations.

The company’s strategic positioning relies on the differentiation of the AirSculpt® procedure from traditional liposuction and non-invasive aesthetic treatments. AIRS has invested in proprietary technologies and branding intended to support pricing power and consumer recognition. Public disclosures indicate ongoing investments in clinic development, technology systems, and patient acquisition capabilities rather than large-scale diversification outside core medical aesthetics. Available public sources do not indicate major transformational acquisitions comparable to larger diversified healthcare companies; however, the company continues to invest in expanding its clinic footprint and procedural offerings.

Geographic Footprint

AIRS is headquartered in Miami Beach, Florida, and operates treatment centers across major metropolitan areas in the United States. Its centers are concentrated in high-income urban and suburban markets including locations in New York, California, Texas, Florida, Illinois, and other population-dense regions. The company’s domestic presence represents the substantial majority of its operational and revenue base.

Internationally, AIRS has maintained a more limited footprint compared with its U.S. operations. Public company disclosures have referenced operations and expansion activity in select international markets, including presence in Canada and the United Kingdom during parts of its operating history. Data regarding the scale and financial contribution of non-U.S. operations remains limited in publicly available disclosures, though the company continues to market itself as an international aesthetic brand.

Leadership & Governance

AIRS leadership combines medical aesthetics expertise, operational management, and public-company governance experience. Founder involvement has remained important to the company’s branding and clinical positioning, particularly through the continued association of the AirSculpt technique with its original developer, Dr. Aaron Rollins. The company’s strategic direction has emphasized premium branding, operational scalability, and consumer-focused elective healthcare delivery.

Key executives and leadership figures include:

• Dennis Dean – Chief Executive Officer
• Vahe Bandarian – Chief Financial Officer
• Dr. Aaron Rollins – Founder and Executive Chairman
• Delray Wannemacher – Chief Operating Officer

Leadership communications in public filings and investor materials have consistently highlighted disciplined center expansion, operational efficiency, physician training, and sustained brand differentiation within the competitive aesthetic procedures market.